Predialysis patients can benefit from phosphate binders, an FDA advisory committee has decided.
An FDA advisory committee has voted in favor of using phosphate binders in predialysis patients with hyperphosphatemia. The products are currently used for patients on dialysis. The FDA's advisory committee on cardiovascular and renal products believes that there is a benefit to extending such therapy before the start of dialysis. Buoyed by the news are drug firms that market products for hyperphosphatemia, such as Genzyme, which sells Renagel (sevelamer hydrochloride), and Shire Pharmaceuticals, which offers noncalcium Fosrenol (lanthanum carbonate).
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.